Industry Insights

  1. Collaborating With Academia For Drug Discovery Targeting Immune-Mediated Diseases 9/16/2022

    Last year, Janssen Biotech and the University of Oxford established a collaboration to understand pathogenic pathways driving immune-mediated inflammatory diseases. They have been creating a cellular map of expressed genes and proteins. This article shares what the collaboration has accomplished so far.

  2. What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry? 2/12/2024

    Novo Holdings, the parent company to Novo Nordisk, announced a deal last week to acquire Catalent, the global CDMO, at a value of $16.5bn. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a stand-alone CDMO. This article unpacks the acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market?”

  3. 5 Hot-Button Issues In Parenteral Packaging 5/16/2023

    Five key issues related to parenteral drug packaging came to the forefront of the PDA Parenteral Packaging Conference held in Venice, Italy, in April.

  4. Common Manufacturing Challenges For LBP Formulations 4/23/2025

    As more companies explore live biotherapeutic products, ensuring stability is likely to be front and center with unique challenges for oral and topical applications.

  5. Continuous Processing For Enhanced Monoclonal Antibody Production 9/14/2023

    mAbs have only recently been leveraged for advanced bioprocessing techniques. Explore highlights from a webinar where experts discussed their unique collaboration for the continuous processing of mAbs.

  6. Gain Speed To GMP Filling 2/24/2025

    Discover the advantages of a filling technology that provides faster readiness to good manufacturing practices (GMP) filling compared with traditional options.

  7. Four Special Fill/Finish Considerations For Vaccine Production

    Examine considerations regarding the handling and process for fill/finish to ensure the stability and purity of your vaccine as well as limit unnecessary waste and cost.

  8. Integrating Analytical Method Development And Quality Control 2/11/2025

    As cell and gene therapies continue to advance, a well-integrated analytical framework will be critical for accelerating development timelines and optimizing regulatory submissions.

  9. Preclinical Model Of Post- Incisional Pain For Efficacy Testing Of Novel Therapeutics 5/16/2025

    Explore how validated preclinical models of incision-induced pain can accelerate the development of effective therapies for postoperative pain by closely mimicking human pain responses.

  10. 4 Insights On CDMO Relationships From A Vaccine Developer 12/28/2022

    After vetting multiple CDMOs, GPN Vaccines selected a strategic partnership with a CDMO that understood the company's vision and the difference between simply manufacturing and actually developing a manufacturing process. GPN Vaccines' CEO and chairman shares his four tips.